Arno Therapeutics to Present Data Validating Target Biomarker at European Cancer Congress 2013

Published: Sep 30, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FLEMINGTON, N.J., Sept. 28, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced data from two preclinical studies supporting its lead compound onapristone to be presented at poster sessions at the European Cancer Congress (ECC) 2013 Annual Meeting, being held September 27-October 1, 2013 in Amsterdam, Netherlands. ECC incorporates three conferences – ECCO, ESMO and ESTRO.

Help employers find you! Check out all the jobs and post your resume.

Back to news